RxDoctor Payments Data

Eric Spann, MD

Family Medicine · Mountain View, ARNPI 1528145695

Payments from drug & device makers

$705in general payments, 2019–2025

Across 40 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$236
  • Amgen$166
  • Xeris Pharmaceuticals, Inc.$81
  • Lilly USA, LLC$43
  • AbbVie$35
  • Sumitomo Pharma America, Inc.$31
  • plus $114 from 7 others

What the payments were for

  • Food & beverage$705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$705 in reported general payments places this provider in the 50th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$232,412
Medicare patients
213
Services billed
4,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bosentan11$85,081
EliquisApixaban83$61,310
OzempicSemaglutide49$46,480
JardianceEmpagliflozin35$33,236
JanuviaSitagliptin Phosphate41$27,658
Combivent RespimatIpratropium/Albuterol Sulfate37$23,270
Tadalafil11$22,726
Emgality PenGalcanezumab-Gnlm25$18,011
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,657
MounjaroTirzepatide12$13,068
Tresiba Flextouch U-100Insulin Degludec25$12,675
FarxigaDapagliflozin Propanediol14$12,172
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,249
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen261$6,128
Praluent PenAlirocumab12$6,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$61,31083 claims
MerckJanuvia$17$27,65841 claims
GSKTrelegy Ellipta$14$16,65718 claims
Lilly USA, LLCMounjaro$43$13,06812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Mountain View

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →